According to Valuates Reports, The global market for AI in Biotechnology was valued at USD 1033 Million in the year 2024 and ...

CHICAGO, IL, UNITED STATES, January 27, 2026 /EINPresswire.com/ — Shinshot Media Inc., an international film production and distribution company, has officially greenlit development of Parallel Time ...

Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

The deal for Intersect, a data center and energy developer, is set to help Google build out its infrastructure for artificial intelligence. By Eli Tan Reporting from Seattle Google has agreed to buy ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...